Valneva Austria GmbH

Quick facts

Phase 3 pipeline

• Biological Vaccine VLA1553 · Immunology / Infectious Disease
  VLA1553 is an inactivated chikungunya virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against chikungunya virus infection.
• Havrix®720 · Immunology / Infectious Disease
  Havrix 720 is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus.
• IC51 · Oncology / Immunology
  IC51 is a therapeutic vaccine that stimulates the immune system to recognize and attack cells infected with human papillomavirus (HPV).
• IC51 Japanese Encephalitis · Infectious Disease / Immunology
  IC51 is an inactivated Japanese encephalitis virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus.
• Japanese Encephalitis purified inactivated vaccine · Infectious Disease / Immunology
  This inactivated vaccine stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus.
• VLA1553 · Infectious Disease
  VLA1553 is a COVID-19 vaccine.
• VLA2001 - adolescent part · Infectious Disease
  VLA2001 is a COVID-19 vaccine that uses a recombinant, replication-incompetent chimpanzee adenovirus vector to express the SARS-CoV-2 spike protein.

Phase 2 pipeline

• IC41
• IC43
• Live-attenuated CHIKV vaccine VLA1553 · Vaccines
  Live-attenuated CHIKV vaccine targets the Chikungunya virus
• VLA1553 full dose
• VLA1553 half dose
• VLA1701
• VLA84

Phase 1 pipeline

• CpG 1018®
• IC47
• IC84
• VLA1601

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Valneva Austria GmbH portfolio CI brief
• Valneva Austria GmbH pipeline updates RSS